Keywords
How to Cite
Abstract
KRAS mutations in patients with metastatic colorectal cancer (CRC) are a negative marker of the effectiveness of anti-EGFR therapy and have prognostic significance. KRAS ge-notyping was performed in the material from patients with metastatic CRC. KRAS mutations were determined in tumor DNA from archival biopsies of 573 patients using PCR and sequencing. Mutations in the exon 2 of the KRAS gene were detected in 36.3% of cases of CRC, while often in women (41.1%) than in men (31.2%). There were identified eight types of KRAS mutations, the most frequent — replacement of G12D (33,7%), G12V (32,7%) and G13D (12,5%). There were revealed differences in the frequency and spectrum of KRAS mutations in CRC of various locations; in tumors of the rectum dominated mutation G12V (39%). The Russian CRC patients find out a higher frequency of mutations G12V and a lower frequency of mutations G13D, than patients from Europe and it should be taken into account when assessing the response of CRC patients with different mutant KRAS status on chemotherapy and targeted therapy.References
Allegra C.J., Jessup J.M., Somerfield M.R. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy // J. Clin. Oncol. — 2009. — № 27. — Р. 20912096.
Al-Mulla F., Milner-White E.J., Going J.J. et al. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression // J. Pathol. — 1999. — Vol. 187. — Р. 433-438.
Andreyev H. J. N., Norman A.R., Cunningham D. et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study // Br. J. Cancer. — 2001. — Vol. 85. — P 692-696.
Breivik J., Meling G.I., Spurkland A. et al. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location // Br. J. Cancer. — 1994. — Vol. 69 — P. 367-371.
Brink, A.F. de Goeij, M.P. Weijenberg, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study // Carcinogenesis. — 2003. — Vol. 24. — Р. 703-710
Cejas P, López-Gómez M., Aguayo C. et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis // PLoS ONE. — 2009. — Vol. 4. — е 8199.
Ciardiello F., Tiepar S., Normanno N. et al. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia // Target Oncol. — 2011 — Vol. 6 — P 133145.
De Roock W., Jonker D.J., Di Nicolantonio F., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab // JAMA. — 2010. — Vol.304. — P 1812-1820.
Imamura Y Morikawa T, Liao X, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers // Clin Cancer Res. — 2012. — Vol. 18. — P. 4753-4763.
Lamy A, Blanchard F, Le Pessot F. et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls // Mod. Pathol. — 2011. — Vol. 24. — P. 1090-1100.
Monticone M, Biollo E, Maffei M. et al. Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context // Mol.Cancer. — 2008. — Vol. 16. — №7. — P 92.
Ogino S., Jeffrey A. Meyerhardt J.A. et al. KRAS mutation in stage III colon cancer and clinical outcome following inter group trial CALGB 89803 // Clin Cancer Res. — 2009 — Vol. 15 — P. 7322-7329.
Oliner K.S., Douillard J-Y, Siena S. et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab plus FOLFOX versus FOLFOX as first-line treatment for metastatic colorectal cancer // ASCO 2013, Permanent Abstract ID: 3511.
Peeters M., Douillard J.Y Van Cutsem E. et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab // J. Clin. Oncol. — 2013. — Vol. 31. — P. 759-765.
Reinacher-Schick A., Schulmann K., Modest D.P et al. Effect of KRAS codon 13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group // BMC Cancer. — 2012. — Vol. 12. — P 349.
Samowitz W.S., Curtin K., Schaffer D. et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage and survival: A population based study // Cancer Epidemiol. Biomarkers and Prevention. — 2000. — Vol. 9. — P. 1193-1197.
Santini D., Loupakis F, Vincenzi B. et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice // Oncologist. — 2008. — Р. 1 270-1 275.
Slattery M.L., Curtin K., Anderson K. et al. Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study // Cancer Res. — 2000. — Vol. 60. — P. 6935-6941.
Tan C., Du Х. KRAS mutation testing in metastatic colorectal cancer //World J. Gastroenterol. — 2012 — Vol. 18.— P. 5171-5180.
Tejpar S., Celik I., Schlichting M. et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab // J. Clin. Oncol.— 2012. — Vol. 30. — P. 3570-3577.
Van Cutsem E, Köhne C.H., Hitre E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer // N. Engl. J. Med. — 2009. — Vol. 360. — №14. — P. 1408-1417.
Velho S., Moutinho C., Cirnes L. et al. BRAF, KRAS and PIK3CA mutations in colorectal polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis? // BMC Cancer. — 2008. — Vol. 8. — P 255.
Vetter, I.R. A. Wittinghofer. The guanine nucleotide-binding switch in three dimensions // Science. — 2001. — Vol. 294. — P. 1299-1304
Vogelstein B., Fearon E.R., Hamilton S.R. et al. Genetic alterations during colorectal-tumor development // N. Engl. J. Med. — 1988. — Vol. 319. — Р 525-532.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...